Sudden sensorineural hearing loss
diseaseOn this page
Also known as acute sensorineural hearing loss by acute acoustic trauma or sudden deafness or surgery induced acoustic traumadeafness, suddensudden deafnesssudden hearing loss
Summary
Sudden sensorineural hearing loss (MONDO:0043373) is a disease and 49 clinical trials. Top therapeutic interventions include dexamethasone, methylprednisolone hemisuccinate, and mecobalamin. A subtype of sudden hearing loss disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Clinical trials: 49
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 40 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | sudden sensorineural hearing loss |
| Mondo ID | MONDO:0043373 |
| MeSH | D003639 |
| Orphanet | 90059 |
| SNOMED CT | 715239002 |
| UMLS | C4275242 |
| MedGen | 907022 |
| GARD | 0012927 |
| Is cancer (heuristic) | no |
Also known as: acute sensorineural hearing loss by acute acoustic trauma or sudden deafness or surgery induced acoustic trauma · deafness, sudden · sudden deafness · sudden hearing loss · sudden sensorineural hearing loss
Disease family
Classification path: disease › human disease › disease by body system or component › auditory system disorder › hearing disorder › hearing loss disorder › sudden hearing loss disorder › sudden sensorineural hearing loss
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Topiramate.
Clinical trials & evidence
Clinical trials
Clinical trials: 49.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 24 |
| PHASE2 | 7 |
| PHASE4 | 4 |
| PHASE3 | 4 |
| EARLY_PHASE1 | 4 |
| PHASE1 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04192656 | PHASE4 | RECRUITING | The Effect of PAP on ISSHL Comorbided With OSA |
| NCT04826237 | PHASE4 | RECRUITING | Oral Statins and Protection From Hearing Loss |
| NCT06878599 | PHASE4 | NOT_YET_RECRUITING | Intratympanic Injection of Dexamethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Hearing Loss |
| NCT06968507 | PHASE4 | RECRUITING | Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss |
| NCT07067801 | PHASE3 | NOT_YET_RECRUITING | Evaluation of Oral Corticosteroid Therapy in Idiopathic Sudden Unilateral Hearing Loss. |
| NCT07113158 | PHASE3 | NOT_YET_RECRUITING | Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss |
| NCT00097448 | PHASE3 | COMPLETED | Sudden Deafness Treatment Trial |
| NCT00335920 | PHASE3 | COMPLETED | Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss |
| NCT03603314 | PHASE2/PHASE3 | COMPLETED | Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss |
| NCT06249919 | PHASE1/PHASE2 | RECRUITING | A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients |
| NCT06467526 | PHASE2 | NOT_YET_RECRUITING | Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss |
| NCT07134075 | PHASE2 | NOT_YET_RECRUITING | Intracochlear Injection of Glucocorticoid |
| NCT07404709 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss |
| NCT07540728 | PHASE2 | NOT_YET_RECRUITING | Trans-round Window Membrane Intracochlear Steroid |
| NCT03255473 | PHASE2 | WITHDRAWN | High Dose Oral Steroids in Sudden Sensorineural Hearing Loss |
| NCT04120116 | PHASE2 | COMPLETED | FX-322 in Adults With Stable Sensorineural Hearing Loss |
| NCT05086276 | PHASE2 | COMPLETED | FX-322 in Adults With Acquired Sensorineural Hearing Loss |
| NCT05403229 | PHASE2 | UNKNOWN | The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss |
| NCT04601909 | PHASE1 | COMPLETED | FX-322 in Adults With Age-Related Sensorineural Hearing Loss |
| NCT04629664 | PHASE1 | COMPLETED | FX-322 in Adults With Severe Sensorineural Hearing Loss |
| NCT04961099 | PHASE1 | UNKNOWN | Phase I Clinical Study of HY01 in Patients |
| NCT06707389 | EARLY_PHASE1 | NOT_YET_RECRUITING | Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness |
| NCT07472023 | EARLY_PHASE1 | ENROLLING_BY_INVITATION | Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss |
| NCT04794842 | EARLY_PHASE1 | UNKNOWN | Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection |
| NCT05849519 | EARLY_PHASE1 | UNKNOWN | Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss |
| NCT05474963 | Not specified | RECRUITING | Sudden Sensorineural Hearing Loss in Wonju Severance Christian Hospital |
| NCT06355102 | Not specified | ENROLLING_BY_INVITATION | The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics |
| NCT06365775 | Not specified | NOT_YET_RECRUITING | Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss |
| NCT06819202 | Not specified | NOT_YET_RECRUITING | Effect of Hyperbaric Oxygen Therapy(HBOT) on Patients With Sudden Sensorineural Hearing Loss(SSNHL) and Coagulation Function |
| NCT06997406 | Not specified | NOT_YET_RECRUITING | ‘Inner Ear Support’ Oral Capsule in Patients With Sudden Sensorineural Hearing Loss |
| NCT07045883 | Not specified | ACTIVE_NOT_RECRUITING | Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss |
| NCT07235488 | Not specified | RECRUITING | Effectiveness of Integrative Medical Treatment in Sudden Hearing Loss |
| NCT07505667 | Not specified | RECRUITING | Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss |
| NCT07575334 | Not specified | RECRUITING | Acupuncture Therapy for Sudden Sensorineural Hearing Loss |
| NCT01265693 | Not specified | COMPLETED | The Effect of Antiviral Therapy With Pegylated Interferon-alpha on Auditory Disability |
| NCT02483650 | Not specified | UNKNOWN | Hyperbaric Oxygen Therapy Registry |
| NCT03706183 | Not specified | UNKNOWN | Ischemia- Modified Albumin Levels in the Sudden Hearing Loss |
| NCT03747874 | Not specified | COMPLETED | OSA and Sudden Sensorineural Hearing Loss |
| NCT03951584 | Not specified | COMPLETED | Prognosis of Vestibular Dysfunction in Patients With Idiopathic Sudden Sensorineural Hearing Loss |
| NCT03974867 | Not specified | UNKNOWN | Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXAMETHASONE | 4 | 5 |
| METHYLPREDNISOLONE HEMISUCCINATE | 4 | 2 |
| MECOBALAMIN | 4 | 1 |
| METHYLPREDNISOLONE | 4 | 1 |
| PHENOL | 4 | 1 |
| TETRACAINE | 4 | 1 |
| METHYLCOBALAMIN | 2 | 1 |
| NADIDE | 2 | 1 |